• A short report on highlights of world-wide development of RIX4414: a latin american experience 

      Linhares, Alexandre da Costa; Ruiz-Palacios, G. M; Guerrero, M. L; Salinas, B; Perez-Schael, I; Clemens, S. A. Costa; Innis, B; Yarzabal, J. P; Vespa, G; Cervantes, Y; Hardt, K; De Vos, B (Elsevier, 2006)
      An oral, human-derived monovalent (G1P1A) rotavirus vaccine, strain RIX4414, has been developed by GlaxoSmithKline, Rixensart, Belgium. The safety, immunogenicity and efficacy of this vaccine were evaluated in a randomized, ...